From the Research
To convert from Trelegy Ellipta to Advair, consult your healthcare provider first, as they will likely prescribe Advair at an appropriate strength based on your current Trelegy dose and condition severity, such as Advair Diskus 250/50 mcg or 500/50 mcg twice daily. When considering the conversion, it's essential to note that Trelegy Ellipta contains three active ingredients (fluticasone furoate, umeclidinium, and vilanterol), while Advair contains two (fluticasone propionate and salmeterol) 1. The transition requires medical supervision because you'll be discontinuing umeclidinium (a long-acting anticholinergic) which helps manage COPD symptoms. Your doctor may need to prescribe a separate anticholinergic inhaler if you have COPD. Some key points to consider during the conversion process include:
- The different salt forms of fluticasone in each product, which have different potencies, making direct conversion not straightforward 1.
- The need for medical supervision to ensure a safe transition and to adjust the dosage as necessary.
- The potential need for a separate anticholinergic inhaler to manage COPD symptoms.
- The importance of monitoring symptoms closely during the transition period and reporting any worsening to your healthcare provider immediately. It's also worth noting that the most recent study 1 suggests that once-daily fluticasone furoate/vilanterol is non-inferior to twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA, which may be relevant when considering the conversion. However, the specific conversion from Trelegy Ellipta to Advair should be guided by the healthcare provider's assessment of the patient's individual needs and condition severity.